1221 Agios Servier
BioCentury & Getty Images


Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission

Dec 21, 2020 | 9:03 PM GMT

Amid a changing cancer landscape, Agios is selling its oncology business for at least $1.8 billion, giving Servier a commercial product and a candidate in Phase III testing. The 12-year-old biotech now sees more value in addressing genetically defined diseases outside of oncology, with a lead program

Read the full 743 word article

How to gain access

Continue reading with a
two-week free trial.